

Scientific Programme

Wednesday, 11 September 2019

08:00 - 08:45	Hot Topic, Hall B Hot Topic 1: Is MS becoming a milder disease, and, if so, why? Chairs O. Andersen (Gothenburg, SE) A. Scalfari (London, UK)
08:00 - 08:15	Trend for decreasing MS disability with increasing calendar year I. Kister (New York, US)
08:15 - 08:30	Slower MS disability progression than previously reported H. Tremlett (Vancouver, CA)
08:30 - 08:45	Increasing incidence of RRMS, decreasing incidence of PPMS, changing gender ratio and decreasing mortality M.-L. Sumelahti (Tampere, FI)
08:00 - 09:30	Educational Session, Hall C Educational Session 1 (MAGNIMS): Update on MAGNIMS guidelines on the use of MRI in the diagnosis and monitoring of multiple sclerosis Basic (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists) Chairs A. Rovira (Barcelona, ES)
08:00 - 08:30	How and when to obtain brain MRI in the diagnosis and monitoring of multiple sclerosis? M. Wattjes (Hannover, DE)
08:30 - 09:00	Value of spinal cord MRI O. Ciccarelli (London, UK)
09:00 - 09:30	When and how to use gadolinium? A. Rovira (Barcelona, ES)

Scientific Programme

08:00 - 09:30	Educational Session, Hall D Educational Session 2: Paediatric MS Basic (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists) Chairs R. Hintzen (Rotterdam, NL) J. Gärtner (Göttingen, DE)
08:00 - 08:30	How to prevent secondary progression in children with MS J. Gärtner (Göttingen, DE)
08:30 - 09:00	The management of anti-MOG positive ADS R. Hintzen (Rotterdam, NL)
09:00 - 09:30	Differential diagnosis C. Hemingway (London, UK)
08:00 - 09:30	Educational Session, Hall F Educational Session 3: B cell therapy of MS - pathology, immunology, clinical effects Basic (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists) Chairs C. Stadelmann (Göttingen, DE) K. Schmierer (London, UK)
08:00 - 08:30	Insights from pathology underpinning B cell-targeted therapy C. Stadelmann (Göttingen, DE)
08:30 - 09:00	Are B cells all that matters? D. Baker (London, UK)
09:00 - 09:30	Relapses, inflammation, progression: Mind our life-changing language K. Schmierer (London, UK)
08:00 - 09:30	Educational Session, Hall G Educational Session 4: Disease modifying treatments in MS Basic (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists) Chairs A. Green (San Francisco, US)

Scientific Programme

08:00 - 08:30

To be announced

08:30 - 09:00

To be announced

09:00 - 09:30

To be announced

08:00 - 09:30

Educational Session, Hall H

Educational Session 5 (RIMS): Rehabilitation in progressive MS

Basic

(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)

Chairs

J. Freeman (Plymouth, UK)

P.L. Eelen (Melsbroek, BE)

08:00 - 08:30

Rehabilitaiton approaches in progressive MS

J. Freeman (Plymouth, UK)

08:30 - 09:00

Bladder and bowel in progressive MS

P.L. Eelen (Melsbroek, BE)

09:00 - 09:30

Caregiver burden in progressive MS

V. Matthews (Herts, UK)

08:55 - 09:40

Hot Topic, Hall B

Hot topic 2: MS Pregnancy in the treatment era

Chairs

M.P. Amato (Florence, IT)

T. Kümpfel (Munich, DE)

08:55 - 09:10

The maternal perspective - When to stop/resume treatment and risks for progression

E. Portaccio (Florence, IT)

09:10 - 09:25

The fetal/child perspective - Risks related drug exposure of the child, breastfeeding and when to reassume medication

K. Hellwig (Bochum, DE)

09:25 - 09:40

Patient awareness about family planning represents a major knowledge gap in multiple sclerosis

M. D'Hooghe (Melsbroek, BE)

Scientific Programme

09:00 - 10:15	Young Scientific Investigators' Session, Hall E Young Scientific Investigators' Session 1 Chairs R. Diem (Heidelberg, DE) C. Teunissen (Amsterdam, NL)
09:45 - 10:30	Hot Topic, Hall B Hot Topic 3: Should we recommend vitamin D supplementation to our MS patients? Chairs P. Sundström (Umeå, SE) K. Munger (Boston, US)
09:45 - 10:00	MS patients should be advised to take vitamin D for MS A. Ascherio (Boston, US)
10:00 - 10:15	Why vitamin D supplementation is not a general advice in MS J. Smolders (Nijmegen, NL)
10:15 - 10:30	Comments on the use of vitamin D in clinical practice, pros and cons E. Mowry (Baltimore, US)
09:45 - 10:30	Hot Topic, Hall C Hot Topic 4: HSCT and stem cell treatment in MS Chairs P.A. Muraro (London, UK) J. Oh (Toronto, CA)
09:45 - 10:00	HSCT for MS - we are ready for prime time J. Burman (Uppsala, SE)
10:00 - 10:15	Hold your horses - HSCT is still an experimental treatment S. Hauser (San Francisco, US)
10:15 - 10:30	Mesenchymal stem cell treatment in MS A. Uccelli (Genoa, IT)
09:45 - 10:30	Hot Topic, Hall D Hot Topic 5: Imaging: Lesion formation and assessment Chairs M.A. Rocca (Milan, IT) A. Rovira (Barcelona, ES)

Scientific Programme

- 09:45 - 10:00** **Evolution of white matter in MS and the role of gadolinium-based contrast agents**
D.S. Reich (Bethesda, US)
- 10:00 - 10:15** **Evolution of cortical lesions in MS**
J. Geurts (Amsterdam, NL)
- 10:15 - 10:30** **A place for PET imaging in MS**
B. Bodini (Paris, FR)
- 09:45 - 10:30** Educational Session, Meeting room T3
Case-based Educational Session 6: How to manage urogenital problems and spasticity
Chairs
P. Flachenecker (Bad Wildbad, DE)
I. Kleiter (Berg, DE)
- 09:45 - 10:05** **Case #1: Multimodal management of spasticity**
P. Flachenecker (Bad Wildbad, DE)
- 10:05 - 10:25** **Case #2: Diagnosis and therapy of voiding difficulties**
I. Kleiter (Berg, DE)
- 09:45 - 10:30** Educational Session, Meeting room T4
Case-based Educational Session 7: How to manage non response to induction therapies?
Chairs
A.J. Coles (Cambridge, UK)
J. Sastre-Garriga (Barcelona, ES)
- 09:45 - 10:05** **Case #1**
A.J. Coles (Cambridge, UK)
- 10:05 - 10:25** **Case #2**
J. Sastre-Garriga (Barcelona, ES)
- 09:45 - 10:30** Educational Session, Meeting room T5
Case-based Educational Session 8: Progressive MS: who should be treated and what should patients expect?
Chairs
J. Chataway (London, UK)
R.J. Fox (Cleveland, US)

Scientific Programme

09:45 - 10:05

Case #1

J. Chataway (London, UK)

10:05 - 10:25

Case #2

R.J. Fox (Cleveland, US)

11:00 - 12:15

Plenary Session, Hall A

Plenary Session 1: Welcome and ECTRIMS Lecture

Chairs

M.P. Amato (Florence, IT)

B. Hemmer (Munich, DE)

J. Hillert (Stockholm, SE)

11:00 - 11:30

Welcome to ECTRIMS 2019

11:30 - 12:15

**ECTRIMS Lecture: Beyond RCTs - why and how observational studies will
guide the future of MS treatment**

M. Trojano (Bari, IT)

12:30 - 13:30

Satellite Symposium, Hall A

Satellite Symposium 1

12:30 - 13:30

Satellite Symposium, Hall B

Satellite Symposium 2

13:45 - 15:15

Scientific Session, Hall B

Scientific Session 1: Remyelination in the course of MS

Chairs

L. Brundin (Stockholm, SE)

R. Franklin (Cambridge, UK)

13:45 - 14:05

Is remyelination possible in MS?

J. Frisen (Stockholm, SE)

14:05 - 14:25

Remyelination from cell based screening to clinical trial

J. Chan (San Francisco, US)

14:25 - 15:15

Platform presentations of related original papers

Scientific Programme

13:45 - 15:15

Scientific Session, Hall C

Scientific Session 2: Safety assessment in the post-approval phase - real world evidence

Chairs

M. Clanet (Toulouse, FR)
O. Gray (Dundonald, UK)

13:45 - 14:05

To use clinical registries in the phase 4 of disease modifying treatment

S. Vukusic (Lyon, FR)

14:05 - 14:25

Genes, environment and safety monitoring in using registries

T. Olsson (Stockholm, SE)

14:25 - 15:15

Platform presentations of related original papers

13:45 - 15:15

Educational Session, Hall F

Educational Session 9: Neurofilament light chains and other fluid biomarkers in MS

Intermediate

(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)

Chairs

J. Kuhle (Basel, CH)
F. Piehl (Stockholm, SE)

13:45 - 14:15

Setting the scene: the relevance of conventional CSF and imaging biomarkers in MS

F. Piehl (Stockholm, SE)

14:15 - 14:45

Assay stability and preanalytics of neurofilament determinations.

E. Willemsse (Amsterdam, NL)

14:45 - 15:15

Blood neurofilament light chain: ready for the clinic?

J. Kuhle (Basel, CH)

13:45 - 15:15

Educational Session, Hall G

Educational Session 10: NMO-spectrum disorders: current concepts and clinical management

Intermediate

(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)

Chairs

J. Palace (Oxford, UK)
F. Paul (Berlin, DE)

Scientific Programme

13:45 - 14:15

NMOSD: an update

J. Palace (Oxford, UK)

14:15 - 14:45

Making the diagnosis in challenging cases with case studies

K. Fujihara (Sendai, JP)

14:45 - 15:15

Treatment challenges in NMOSD with case studies

F. Paul (Berlin, DE)

13:45 - 15:15

Educational Session, Hall H

**Educational Session 11: Getting it right - accurate
diagnosis and avoiding misdiagnosis of MS**

Basic

(Basic = neurologists in training, non MS-specialists / Intermediate = board
examined neurologists / Advanced = MS specialists)

Chairs

G. Arrambide (Barcelona, ES)

W. Brownlee (London, UK)

13:45 - 14:05

MS: What's typical, what's not?

W. Brownlee (London, UK)

14:05 - 14:25

Applying the 2017 McDonald criteria to make an accurate diagnosis

G. Arrambide (Barcelona, ES)

14:25 - 14:45

Tips for avoiding misdiagnosis

A. Solomon (Burlington, US)

14:45 - 15:15

Interactive case presentations for discussion

G. Arrambide (Barcelona, ES)

W. Brownlee (London, UK)

A. Solomon (Burlington, US)

14:00 - 15:00

Satellite Symposium, Hall A

**European Charcot Foundation Symposium: Explaining
environmental impact in MS**

Chairs

G. Comi (Milan, IT)

M.P. Amato (Florence, IT)

14:00 - 14:15

**New epidemiological evidence of the role of environment on MS risk and
evolution**

A. Ascherio (Boston, US)

Scientific Programme

- 14:15 - 14:30** **Role of intestinal microbiome**
H. Wekerle (Martinsried, DE)
- 14:30 - 14:45** **Smoke and air pollution exposure: impact on MS**
L. Alfredsson (Stockholm, SE)
- 14:45 - 15:00** **Discussion**
- Young Scientific Investigators' Session, Hall D
- 14:00 - 15:15** **Young Scientific Investigators' Session 2**
- Chairs**
L. Airas (Turku, FI)
D. Ontaneda (Cleveland, US)
- Nurses' Session, Hall E
- 14:00 - 15:15** **Nurses' Session 1**
- Scientific Session, Hall A
- 15:45 - 17:15** **Scientific Session 3: DMT in RRMS**
- Chairs**
F. Sellebjerg (Copenhagen, DK)
E. Kubala Havrdová (Prague, CZ)
- 15:45 - 16:05** **DMTs in RRMS 2019 - what remains to be achieved**
G. Giovannoni (London, UK)
- 16:05 - 16:25** **Comparative effectiveness studies in RRMS in the real world**
T. Spelman (Stockholm, SE)
- 16:25 - 17:15** **Platform presentations of related original papers**
- Scientific Session, Hall B
- 15:45 - 17:15** **Scientific Session 4: What determines the long-term outcome of MS?**
- Chairs**
M. Magyari (Copenhagen, DK)
K. Fujihara (Sendai, JP)
- 15:45 - 16:05** **Course of MS in the era of disease modification**
A. Manouchehrinia (Stockholm, SE)

Scientific Programme

16:05 - 16:25

Co-morbidities and the course of MS

R.A. Marrie (Winnipeg, CA)

16:25 - 17:15

Platform presentations of related original papers

Scientific Session, Hall C

15:45 - 17:15

Burning Debate: It is inappropriate to prescribe interferon-beta and glatiramer acetate for active relapsing MS

This burning debate will address the topical motion: From a healthcare provider perspective, it is now inappropriate to prescribe 1st generation injectables (interferon-beta and glatiramer acetate) to newly diagnosed patients with active relapsing MS.

The live audience are encouraged to participate in the session by tweeting comments and questions using #burningdebate. At the end of the two presentations, the audience can vote on who should win the debate through twitter.

Chairs

J. Palace (Oxford, UK)

15:45 - 15:50

Introduction

J. Palace (Oxford, UK)

15:50 - 16:10

Against

M. Zakaria (Cairo, EG)

16:10 - 16:30

For

G. Kobelt (Stockholm, SE)

16:30 - 17:15

Discussion

Young Scientific Investigators' Session, Hall D

15:45 - 17:00

Young Scientific Investigators' Session 3

Chairs

A. Oturai (Copenhagen, DK)

G. Comi (Milan, IT)

Nurses' Session, Hall E

15:45 - 17:00

Nurses' Session 2

Scientific Programme

15:45 - 17:15	<p>Educational Session, Hall F</p> <p>Educational Session 12 (MAGNIMS): Big data and deep learning: new avenues for MRI research in MS?</p> <p>Advanced (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</p> <p>Chairs M.A. Rocca (Milan, IT) H. Vrenken (Amsterdam, NL)</p>
15:45 - 16:15	<p>Big data in MRI research in MS M.A. Rocca (Milan, IT)</p>
16:15 - 16:45	<p>Collaborative research environments and crowd-sourced science in MRI in MS H. Vrenken (Amsterdam, NL)</p>
16:45 - 17:15	<p>Machine learning in MRI research in MS D. Pareto (Barcelona, ES)</p>
15:45 - 17:15	<p>Educational Session, Hall G</p> <p>Educational Session 13: Pregnancy management in MS</p> <p>Level: Basic (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</p> <p>Chairs M.K. Houtchens (Brookline, US) K. Hellwig (Bochum, DE)</p>
15:45 - 16:15	<p>Reproductive counseling in MS: guidance and guidelines in 2019 M.K. Houtchens (Brookline, US)</p>
16:15 - 16:45	<p>Disease modifying medications in women with MS planning a pregnancy: 2019 update K. Hellwig (Bochum, DE)</p>
16:45 - 17:15	<p>Postpartum management in women with MS R. Bove (San Francisco, US)</p>

Scientific Programme

15:45 - 17:15

Educational Session, Hall H

Educational Session 14: Diagnosis and management of other neuroinflammatory diseases (CLIPPERS, anti-GFAP, neurosarcoidosis, other systemic autoimmune diseases with CNS involvement)

Basic
(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)

Chairs

D.M. Wingerchuk (Scottsdale, US)
E. Flanagan (Rochester, US)

15:45 - 16:15

Autoimmune GFAP astrocytopathy: characteristics and comparison to AQP4 and MOG-related disease

E. Flanagan (Rochester, US)

16:15 - 16:45

Neurosarcoidosis, CNS vasculitis, and Behcet's disease

J. Gelfand (San Francisco, US)

16:45 - 17:15

CLIPPERS and other rare CNS inflammatory syndromes

D.M. Wingerchuk (Scottsdale, US)

17:15 - 19:15

Poster Sessions, Poster exhibition

Poster Session 1

18:15 - 19:15

Satellite Symposium, Hall A

Satellite Symposium 3

18:15 - 19:15

Satellite Symposium, Hall B

Satellite Symposium 4

Scientific Programme

Thursday, 12 September 2019

07:30 - 08:30	Satellite Symposium, Hall B Satellite Symposium 5
08:00 - 09:30	Educational Session, Hall E Educational Session 15: How do our treatments impact the immune system? Basic (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists) Chairs R. Liblau (Toulouse, FR) L. Klotz (Münster, DE)
08:00 - 08:30	Impact of first-line MS treatments on the immune system L. Klotz (Münster, DE)
08:30 - 09:00	Migration-targeting therapies in MS: impact on immune responses R. Liblau (Toulouse, FR)
09:00 - 09:30	Cell-depleting strategies in MS: impact on immune responses A. Bar-Or (Philadelphia, US)
08:00 - 09:30	Educational Session, Hall F Educational Session 16 (IMSCOGS): Cognitive dysfunction in MS Basic (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists) Chairs R.H. Benedict (Buffalo, US) M.P. Amato (Florence, IT)
08:00 - 08:30	Epidemiology and risk factors: an update M.P. Amato (Florence, IT)
08:30 - 09:00	How to diagnose and monitor in clinical practice R.H. Benedict (Buffalo, US)
09:00 - 09:30	How to manage: recent developments J. DeLuca (West Orange, US)

Scientific Programme

08:30 - 09:30

Free Communications, Hall A

Free Communication 1

Chairs

J. Palace (Oxford, UK)
S. Houry (Beirut, LB)

08:30 - 09:30

Free Communications, Hall B

Free Communication 2

Chairs

A.J. Thompson (London, UK)
E. Gulowsen Celius (Oslo, NO)

08:30 - 09:30

Free Communications, Hall C

Free Communication 3

Chairs

A. Achiron (Tel Aviv, IL)
C. Lebrun (Nice, FR)

10:00 - 11:30

Scientific Session, Hall A

Scientific Session 5: DMT in progressive MS

Chairs

R.J. Fox (Cleveland, US)
B. Bielkova (Bethesda, US)

10:00 - 10:20

DMTs in progressive MS 2019 - what remains to be achieved

X. Montalban (Toronto, CA)

10:20 - 10:40

How to design RCTs for SPMS

J. Chataway (London, UK)

10:40 - 11:30

Platform presentations of related original papers

10:00 - 11:30

Scientific Session, Hall B

Scientific Session 6: Genes and progression/course

Chairs

S. Sawcer (Cambridge, UK)
L. Barcellos (Berkeley, US)

10:00 - 10:20

In search of genetic regulation of progression and severity of MS

I. Kockum (Stockholm, SE)

Scientific Programme

10:20 - 10:40	HLA variation and MS L. Fugger (Oxford, UK)
10:40 - 11:30	Platform presentations of related original papers
	Scientific Session, Hall C
10:00 - 11:30	Scientific Session 7: How to achieve a structured assessment and quality assurance in MS care Chairs K. Fink (Stockholm, SE) P. Matthews (London, UK)
10:00 - 10:20	Patient monitoring by wearable devices integrated in MS care T. Chitnis (Boston, US)
10:20 - 10:40	To design, implement and sustain big data collection in MS H. Butzkueven (Melbourne, AU)
10:40 - 11:30	Platform presentations of related original papers
	Scientific Session, Hall D
10:00 - 11:30	Scientific Session RIMS 1: How can rehabilitation influence the progression of MS? Chairs S. Johansson (Stockholm, SE) J. Freeman (Plymouth, UK)
10:00 - 10:20	Exercise therapy in MS - a disease modifying role? U. Dalgas (Aarhus, DK)
10:20 - 10:40	Coping strategies when living with MS progression L.B. Strober (East Hanover, US)
10:40 - 11:30	Platform presentations of related original papers

Scientific Programme

10:00 - 11:30	<p>Educational Session, Hall E</p> <p>Educational Session 17: Pharmacovigilance and multiple sclerosis in the post-marketing setting: opportunity and lessons learned</p> <p>Advanced (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</p> <p>Chairs H. Tremlett (Vancouver, CA) M. Magyari (Copenhagen, DK)</p>
10:00 - 10:30	<p>Using linked health administrative and clinical data to investigate drug safety in MS</p> <p>H. Tremlett (Vancouver, CA)</p>
10:30 - 11:00	<p>Using registry data to investigate drug safety in MS</p> <p>M. Magyari (Copenhagen, DK)</p>
11:00 - 11:30	<p>Evolution of biological agents: how established drugs can become less safe</p> <p>D. Hunt (Edinburgh, UK)</p>
10:00 - 11:30	<p>Educational Session, Hall F</p> <p>Educational Session 18: Antibodies and Complement in MS Spectrum Disorders</p> <p>Intermediate (Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</p> <p>Chairs J. Bennet (Denver, US) J. Lünemann (Münster, DE)</p>
10:00 - 10:30	<p>Antibody- and complement-mediated effector functions</p> <p>J. Lünemann (Münster, DE)</p>
10:30 - 11:00	<p>Antibody-mediated pathogenesis in central and peripheral neuroinflammatory disorders</p> <p>J. Bennet (Denver, US)</p>
11:00 - 11:30	<p>Therapeutic complement inhibition in neuroinflammatory diseases</p> <p>R. Mantegazza (Milan, IT)</p>
10:00 - 11:00	<p>Meet the Expert, Hall H</p> <p>Meet the Expert 1</p>

Scientific Programme

11:45 - 12:30	Hot Topic, Hall A Hot Topic 6: B-cells in the pathogenesis of MS Chairs A. Svenningsson (Stockholm, SE) R. Magliozzi (Verona, IT)
11:45 - 12:00	Rationale of B-cell therapy in MS D. Baker (London, UK)
12:00 - 12:15	Rituximab is a reasonable alternative in MS treatment F. Piehl (Stockholm, SE)
12:15 - 12:30	Rituximab is not a reasonable alternative in MS treatment M.T. Wallin (Washington, US)
11:45 - 12:30	Hot Topic, Hall B Hot Topic 7: Symptomatic treatment Chairs A.-M. Landtblom (Uppsala, SE) R. Papais-Alvarenga (Rio de Janeiro, BR)
11:45 - 12:00	Main challenges in symptomatic MS treatment E. Maillart (Paris, FR)
12:00 - 12:15	Neuromodulation: a potential approach to management of symptoms in MS L. Leocani (Milan, IT)
12:15 - 12:30	Symptomatic pharmacotherapy and patient education strategies in progressive MS - an inventory J. Sastre-Garriga (Barcelona, ES)
11:45 - 12:30	Hot Topic, Hall C Hot Topic 8: Neuromyelitis optica spectrum disorders Chairs R. Marignier (Lyon, FR) A. Bar-Or (Philadelphia, US)
11:45 - 12:00	New emerging treatments in NMOSD B. Weinshenker (Rochester, US)
12:00 - 12:15	The spectrum of demyelinating diseases in children B. Banwell (Philadelphia, US)
12:15 - 12:30	Pathogenesis of human antibodies against MOG E. Meinl (Martinsried, DE)

Scientific Programme

11:45 - 12:30	Hot Topic, Hall D Hot topic 9: Patients' voice to develop MS care: MS PROMs Chairs J. Cohen (Cleveland, US) P.F. Zaratin (Genoa, IT)
11:45 - 12:00	20 years of MSIS-29 - importance of an MS specific QoL scale J. Hobart (Plymouth, UK)
12:00 - 12:15	PROMs: Supporting patient-centred care M. Finlayson (Kingston, CA)
12:15 - 12:30	PROMs in standardized MS care A. Solari (Milan, IT)
11:45 - 12:45	Meet the Expert, Hall H Meet the Expert 2
11:45 - 12:45	Educational Session, Meeting room T3 Case-based Educational Session 19: When to stop treatment? Chairs G. Edan (Rennes, FR) E. Le Page (Rennes, FR)
11:45 - 12:15	Case #1: When to stop in relapsing remitting multiple sclerosis (RRMS) patient E. Le Page (Rennes, FR)
12:15 - 12:45	Case #2: When to stop in stop in secondary progressive multiple sclerosis (SPMS) patient G. Edan (Rennes, FR)
13:00 - 14:00	Satellite Symposium, Hall A Satellite Symposium 6
13:00 - 14:00	Satellite Symposium, Hall B Satellite Symposium 7

Scientific Programme

14:15 - 15:45	Scientific Session, Hall A Scientific Session 8: Pathological correlates of progression in MS Chairs L. Bø (Bergen, NO) C. Stadelmann (Göttingen, DE)
14:15 - 14:35	Multiple sclerosis pathogenesis: what are the missing pieces? W. Brück (Göttingen, DE)
14:35 - 14:55	Potential biological mechanisms behind MS progression J. Van Horssen (Amsterdam, NL)
14:55 - 15:45	Platform presentations of related original papers
14:15 - 15:45	Scientific Session, Hall B Scientific Session 9: Beyond EDSS - towards a comprehensive assessment of MS course Chairs S. Fredrikson (Stockholm, SE) A. Langer-Gould (Pasadena, US)
14:15 - 14:35	Cognitive assessment in MS - rationale and tools D. Langdon (London, UK)
14:35 - 14:55	Neuro-QoL in MS - tomorrow's standard outcome? D. Miller (Cleveland, US)
14:55 - 15:45	Platform presentations of related original papers
14:15 - 15:45	Scientific Session, Hall C Scientific Session 10: EBV and HHV-6 and the pathogenesis of MS Chairs A. Fogdell-Hahn (Stockholm, SE) R. Hohlfeld (Munich, DE)
14:15 - 14:35	A role for HHV-6 in MS is still a valid hypothesis S. Jacobson (Bethesda, US)
14:35 - 14:55	The role of EBV in MS immunology? C. Münz (Zurich, CH)
14:55 - 15:45	Platform presentations of related original papers

Scientific Programme

14:15 - 15:45

Scientific Session, Hall D

Scientific Session RIMS 2: Challenges in cognitive rehabilitation

Chairs

A. Solari (Milan, IT)
C. Dettmers (Konstanz, DE)

14:15 - 14:35

Strategy training - curse or blessing?

P. Hämäläinen (Turku, FI)

14:35 - 14:55

Cognitive rehabilitation for attention and memory in multiple sclerosis: results of the CRAMMS trial

R. Dasnair (Nottingham, UK)

14:55 - 15:45

Platform presentations of related original papers

14:15 - 15:45

Educational Session, Hall E

Educational Session 20: Immunisation in MS

Basic
(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)

Chairs

S. Vukusic (Lyon, FR)
J. Correale (Buenos Aires, AR)

14:15 - 14:45

Vaccines and the risk of MS

J. Correale (Buenos Aires, AR)

14:45 - 15:15

Vaccines and the risk of relapses

J. Frederiksen (Copenhagen, DK)

15:15 - 15:45

Vaccines and DMTs

S. Vukusic (Lyon, FR)

14:15 - 15:45

Educational Session, Hall F

Educational Session 21: Comprehensive appraisal of MS studies

Advanced
(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)

Chairs

M.P. Sormani (Genoa, IT)
F. Deisenhammer (Innsbruck, AT)

Scientific Programme

- 14:15 - 14:45** **How to assess and summarize study**
E. Hernández Martínez-Lapiscina (Barcelona, ES)
- 14:45 - 15:15** **Data analyses, interpretation, misinterpretation, and biases**
M.P. Sormani (Genoa, IT)
- 15:15 - 15:45** **Interpretation of analytical/deductive statistics**
F. Deisenhammer (Innsbruck, AT)
- 14:15 - 15:15** Meet the Expert, Hall H
Meet the Expert 3
- 16:15 - 17:15** Free Communications, Hall A
Free Communication 4
Chairs
M. Tintoré (Barcelona, ES)
M. Pugliatti (Ferrara, IT)
- 16:15 - 17:15** Free Communications, Hall B
Free Communication 5
Chairs
P.S. Sørensen (Copenhagen, DK)
D. Horáková (Prague, CZ)
- 16:15 - 17:15** Free Communications, Hall C
Free Communication 6
Chairs
H.F. Harbo (Oslo, NO)
J. Correale (Buenos Aires, AR)
- 16:15 - 17:00** Hot Topic, Hall D
**Hot topic 10: Epigenetics in MS: implications for
pathogenesis and disease management**
Chairs
J. Lechner-Scott (Newcastle, AU)
G. Castelo-Branco (Stockholm, SE)

Scientific Programme

16:15 - 16:30	Epigenetic mechanisms of MS risk factors (DR15 and smoking) M. Jagodic (Stockholm, SE)
16:30 - 16:45	Epigenetic mechanisms in MS brain
16:45 - 17:00	Identification of oligodendrocyte loss using circulating DNA methylation
	Meet the Expert, Hall H
16:15 - 17:15	Meet the Expert 4
	Educational Session, Meeting room T3
16:15 - 17:15	Case-based Educational Session 22 (RIMS): Progressive MS: losing mobility
	Chairs V. de Groot (Amsterdam, NL) A. Guldhammer Skjerbæk (Ry, DK)
16:15 - 16:35	Diagnosing and treating gait problems using gait analysis V. de Groot (Amsterdam, NL)
16:35 - 16:55	Ensuring an effective training to deal with mobility loss A. Guldhammer Skjerbæk (Ry, DK)
	Poster Sessions, Poster exhibition
17:15 - 19:15	Poster Session 2
	Satellite Symposium, Hall A
18:15 - 19:15	Satellite Symposium 8
	Satellite Symposium, Hall B
18:15 - 19:15	Satellite Symposium 9

Scientific Programme

Friday, 13 September 2019

07:30 - 08:30	Satellite Symposium, Hall A Satellite Symposium 10
08:30 - 10:00	Scientific Session, Hall A Scientific Session 11: Immunopathogenesis and antigen-specific therapies Chairs E. Iacobaeus (Stockholm, SE) F. Zipp (Mainz, DE)
08:30 - 08:50	Antigenspecific MS treatment revisited - recent development and prospects R. Martin (Zurich, CH)
08:50 - 09:10	A future for antigenspecific immunotherapy for multiple sclerosis D. Wraith (Birmingham, UK)
09:10 - 10:00	Platform presentations of related original papers
08:30 - 10:00	Scientific Session, Hall B Scientific Session 12: Registry-based MS research Chairs K.-M. Myhr (Bergen, NO) M. Trojano (Bari, IT)
08:30 - 08:50	Infection studies in registry-based MS research S. Montgomery (Stockholm, SE)
08:50 - 09:10	What registries reveal on child onset MS M. Magyari (Copenhagen, DK)
09:10 - 10:00	Platform presentations of related original papers
08:30 - 10:00	Scientific Session, Hall C Scientific Session 13: Soluble and electrophysiological biomarkers Chairs J. Salzer (Umeå, SE) S. Gnanapavan (London, UK)

Scientific Programme

- 08:30 - 08:50** **Moving from CSF to blood: monitoring disease activity in MS using serum neurofilament light protein**
J. Lycke (Gothenburg, SE)
- 08:50 - 09:10** **OCT as a prognostic marker**
P. Calabresi (Baltimore, US)
- 09:10 - 10:00** **Platform presentations of related original papers**
- Scientific Session, Hall D
- 08:30 - 10:00** **Scientific Session 14: Socioeconomic outcomes in MS**
- Chairs**
K. Alexandersson (Stockholm, SE)
P. Flachenecker (Bad Wildbad, DE)
- 08:30 - 08:50** **Burden and cost of multiple sclerosis**
G. Kobelt (Stockholm, SE)
- 08:50 - 09:10** **Socioeconomy - accessible and valid outcome measures in MS**
J. Hillert (Stockholm, SE)
- 09:10 - 10:00** **Platform presentations of related original papers**
- Educational Session, Hall E
- 08:30 - 10:00** **Educational Session 23: Radiologically Isolated Syndrome (RIS): incidental MRI findings or subclinical MS?**
- Basic
(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)
- Chairs**
N. De Stefano (Siena, IT)
C. Lebrun (Nice, FR)
- 08:30 - 09:00** **RIS: just incidental MRI findings or a real disease entity?**
D. Okuda (Dallas, US)
- 09:00 - 09:30** **Can we diagnose subclinical MS?**
N. De Stefano (Siena, IT)
- 09:30 - 10:00** **The management of RIS**
C. Lebrun (Nice, FR)

Scientific Programme

08:30 - 10:00

Educational Session, Hall F

Educational Session 24: Pathology of MS

Advanced

(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)

Chairs

H. Lassmann (Wien, AT)

O. Howell (Swansee, UK)

08:30 - 09:00

The inflammatory response in the MS brain: implications for pathogenesis and therapy

H. Lassmann (Wien, AT)

09:00 - 09:30

The spectrum of cortical pathology in the MS brain: when, where and why

O. Howell (Swansee, UK)

09:30 - 10:00

Pathological correlates of 7T MRI: how far can we image MS pathology in the living patient

S. Hametner (Vienna, AT)

10:30 - 12:00

Scientific Session, Hall A

Scientific Session 15: How to optimise long term benefit of MS treatment, therapeutic strategy

Chairs

T. Ziemssen (Dresden, DE)

E. Kingwell (Vancouver, CA)

10:30 - 10:50

Why induction therapy is the preferred principle over treatment escalation

A.J. Coles (Cambridge, UK)

10:50 - 11:10

Why escalation therapy is the preferred principle over treatment induction

E. Waubant (San Francisco, US)

11:10 - 12:00

platform presentations of related original papers

10:30 - 12:00

Scientific Session, Hall B

Scientific Session 16: Quantitative imaging biomarkers

Chairs

T. Granberg (Stockholm, SE)

C. Granziera (Basel, CH)

10:30 - 10:50

Quantification and interpretation of brain atrophy in MS

N. De Stefano (Siena, IT)

Scientific Programme

10:50 - 11:10	Quantitative MRI and imaging biomarkers of the spinal cord in MS O. Ciccarelli (London, UK)
11:10 - 12:00	platform presentations of related original papers
	Scientific Session, Hall C
10:30 - 12:00	ECTRIMS - EAN Session: Emerging concepts of relapsing and progressive MS Chairs C. Enzinger (Graz, AT) M.P. Amato (Florence, IT)
10:30 - 11:00	The contribution of relapses to progression - what do we learn from biomarker studies? L. Kappos (Basel, CH)
11:00 - 11:30	Assessing and understanding relapse independent progression in different disease stages G. Comi (Milan, IT)
11:30 - 12:00	MRI measures of neuroinflammation and neurodegeneration M.A. Rocca (Milan, IT)
	Scientific Session, Hall D
10:30 - 12:00	Scientific Session RIMS 3: Rehabilitation: one size doesn't fit all Chairs S. Coote (Limerick, IR) V. de Groot (Amsterdam, NL)
10:30 - 10:50	Patient centered approach in rehabilitation D. Kos (Leuven, BE)
10:50 - 11:10	Wearable technology: how can we use it to measure and improve functioning in MS G. Brichetto (Genoa, IT)
11:10 - 12:00	Platform presentations of related original papers

Scientific Programme

10:30 - 12:00

Educational Session, Hall E

Educational Session 25: Preventing, monitoring and managing infectious complications of MS therapies

Basic

(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)

Chairs

A. Vidal-Jordana (Barcelona, ES)
L. Prosperini (Rome, IT)

10:30 - 11:00

Prevention of infectious complications of MS therapies

A. Vidal-Jordana (Barcelona, ES)

11:00 - 11:30

Monitoring MS therapies to rapidly detect infectious complications

L. Prosperini (Rome, IT)

11:30 - 12:00

Managing infectious complications of MS therapies

E. Ciampi (Santiago, CL)

10:30 - 12:00

Educational Session, Hall F

Educational Session 26: Which remyelination strategies are most promising?

Advanced

(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)

Chairs

M. Simons (Munich, DE)
G. Castelo-Branco (Stockholm, SE)

10:30 - 11:00

Remyelination: insights from mouse models and transcriptomic studies

G. Castelo-Branco (Stockholm, SE)

11:00 - 11:30

Remyelination: insights from human neuropathology

C. Stadelmann (Göttingen, DE)

11:30 - 12:00

Remyelination: molecular mechanisms and therapeutic developments

M. Simons (Munich, DE)

Scientific Programme

12:00 - 13:00

Scientific Session, Hall F

Google Hangout

A google hangout broadcast from ECTRIMS with Barts MS researchers with people with MS sharing highlights from the meeting.
View the livestream on the BartsMS YouTube page!

Chairs

R. Aldam (London, UK)
M. Marta (London, UK)

12:00 - 13:00

ECTRIMS 2019 Highlights

D. Baker (London, UK)
S. Gnanapavan (London, UK)

12:15 - 14:15

Poster Sessions, Poster exhibition

Poster Session 3

13:00 - 14:00

Satellite Symposium, Hall A

Satellite Symposium 11

13:00 - 14:00

Satellite Symposium, Hall B

Satellite Symposium 12

14:15 - 15:30

Scientific Session, Hall A

Scientific Session 17: Late Breaking News

Chairs

T. Derfuss (Basel, CH)
M. Zeineddine (Beirut, LB)

16:00 - 18:00

Plenary Session, Hall A

Plenary Session 2 - ECTRIMS Awards, ECTRIMS Honorary Members, Charcot Lecture and ECTRIMS 2019 Highlights

Chairs

M.P. Amato (Florence, IT)
B. Hemmer (Munich, DE)
J. Hillert (Stockholm, SE)

Scientific Programme

16:00 - 16:45	Presentation of selected poster awards, awards for best oral presentations by young researchers, awards for best RIMS poster and best RIMS oral presentation, the MSIF award as well announcement of ECTRIMS Honorary Members
16:45 - 17:15	Charcot Lecture
17:15 - 17:35	Scientific highlights A.E. Miller (New York, US) C. Lubetzki (Paris, FR)
17:35 - 17:55	Clinical highlights C.A. Young (Liverpool, UK) A. Siva (Istanbul, TR)
17:55 - 18:00	Welcome to MSWashingtonDC2020